Guidance

MenB vaccine (Bexsero®): patient group direction template

PGD template to support the national meningococcal group B (Bexsero®) vaccination programme and public health management of meningococcal disease.

• From: UK Health Security Agency
• Published: 14 August 2015
• Last updated: 3 June 2025
  Show all updates

  1. 3 June 2025

     Added version 8 - see page 4 for change history.

  2. 22 January 2025

     Added version version 7.0 - see change history on page 4.

  3. 10 January 2023

     Added version v6.00 - see change history on page 3.

  4. 12 February 2021

     Added version v05.00 - see change history on page 2.

  5. 15 February 2019

     Added version V04.00 - updated details regarding permissible use of Immform supplies of 4CMenB and removal of the black triangle status.

  6. 11 May 2018

     Template revised to align with the new Guidance for the Public Health Management of Meningococcal Disease in the UK.

  7. 1 March 2017

     Updated dosing recommendations for individuals with incomplete vaccination status, and revision to allow administration of booster dose in the left thigh.

  8. 14 August 2015

     First published.

Applies to England

Documents

MenB vaccine (Bexsero®): patient group direction (PGD) template

Ref: UKHSA gateway number GOV-18484

MS Word Document, 165 KB

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of MenB vaccine to individuals from 8 weeks of age eligible for the national routine meningococcal group B vaccination programme and to individuals for the prevention of secondary cases of meningococcal group B disease in accordance with the guidance for the public health management of meningococcal disease in the UK.

MenB vaccine PGD version version 8.0 is valid from 1 July 2025 to 28 February 2028.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.